Free tool
FAERS Monitor: Concerta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021121 or its brand name (Concerta, Methylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
24,565
Serious
15,132
62% of reports
Hospitalization
5,015
Death reported
790
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,748
- headache1,273
- off label use1,230
- nausea1,120
- fatigue1,103
- anxiety1,100
- insomnia907
- depression825
- suicidal ideation825
- decreased appetite755
- aggression720
- disturbance in attention720
- somnolence697
- dizziness693
- vomiting687
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 501 |
| 2005 | 509 |
| 2006 | 503 |
| 2007 | 554 |
| 2008 | 549 |
| 2009 | 622 |
| 2010 | 619 |
| 2011 | 561 |
| 2012 | 669 |
| 2013 | 626 |
| 2014 | 639 |
| 2015 | 2,084 |
| 2016 | 1,658 |
| 2017 | 1,486 |
| 2018 | 1,417 |
| 2019 | 1,422 |
| 2020 | 1,208 |
| 2021 | 1,069 |
| 2022 | 1,607 |
| 2023 | 1,970 |
| 2024 | 1,631 |
| 2025 | 1,550 |
| 2026 | 1,111 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,594 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aggressionSignal | 720 | 12.5 | 11.6 | 7,502 |
| disturbance in attentionSignal | 720 | 11.6 | 10.8 | 6,868 |
| suicidal ideationSignal | 825 | 7.8 | 7.3 | 4,843 |
| anxietySignal | 1,100 | 3.3 | 3.1 | 1,797 |
| depressionSignal | 825 | 3.1 | 2.9 | 1,189 |
| somnolenceSignal | 697 | 3.0 | 2.8 | 915 |
| insomniaSignal | 907 | 2.9 | 2.7 | 1,156 |
| decreased appetiteSignal | 755 | 2.8 | 2.6 | 871 |
| drug ineffective | 2,748 | 1.8 | 1.7 | 1,013 |
| headache | 1,273 | 1.7 | 1.6 | 411 |
| vomiting | 687 | 1.3 | 1.2 | 35 |
| fatigue | 1,103 | 1.2 | 1.1 | 43 |
| nausea | 1,120 | 1.2 | 1.1 | 43 |
| off label use | 1,230 | 1.2 | 1.1 | 44 |
| dizziness | 693 | 1.2 | 1.1 | 21 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.